Associate Editor, European Journal of Cardio-Thoracic Surgery Section Editor, Asian Cardio-Vascular and Thoracic Annals International Director, Society of Thoracic Surgeons (STS) Council Member, Asian Society for Cardio-Vascular and Thoracic Surgery (ASCVTS) Board Member, Asia Thoracoscopic Surgery Education Platform (ATEP) Council Member, Hong Kong Society of Minimal Access Surgery (HKSMAS) Program Committee, International Association for the Study of Lung Cancer (IASLC) Specialist Advisor, Hong Kong Society of Medical Oncology Dr Sihoe received his medical training at the University of Cambridge, and after working in Scotland and England, he returned to practice Cardiothoracic Surgery in Hong Kong and China, with a special interest in minimally invasive Video-Assisted Thoracic Surgery (VATS). He was Clinical Associate Professor of the Department of Surgery at the University of Hong Kong and Chief of Thoracic Surgery at the University of Hong Kong Shenzhen Hospital before recently moving to private practice in Hong Kong. Dr Sihoe is currently Consultant in Cardiothoracic Surgery at the CUHK Medical Center in Hong Kong, and Honorary Consultant in Cardiothoracic Surgery at the Gleneagles Hong Kong Hospital. Dr Sihoe is an internationally recognized advocate of ‘next generation’ VATS techniques – especially uniportal and needlescopic chest surgery. He has authored or co-authored over 200 peer-reviewed journal articles, conference abstracts and book chapters in the international literature. He is an avid medical educator, and has been invited to perform surgery and lecture at surgical conferences and educational events on every continent in the world. His work in thoracic surgery and clinical research has won multiple awards – including from the European Society of Thoracic Surgeons (ESTS) and the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS). In 2018, Dr Sihoe was the recipient of the Medical Sciences Technical Award (2nd Class) from the Chinese Medical Association. Dr Sihoe has previously served in leadership roles in multiple Cardio-Thoracic Surgery societies in Europe and Asia, and he continues to actively to promote clinical and academic practices in the specialty through teaching and academic engagements around the world. Dr Sihoe’s indexed academic and research output can be found at: https://www.ncbi.nlm.nih.gov/pubmed/?term=sihoe+a+%5Bau%5D

Associate Professor Chee Lee works as a Research Fellow and Clinical Lead at the CTC. He is also a staff specialist in medical oncology at St George Hospital and the Sutherland Hospital; and a visiting medical oncologist at St George Private Hospital. Chee’s clinical practice is based around lung, gynaecological and other advanced cancers. His clinical and research interests are focused on identifying and developing better strategies to personalise treatment and improve outcomes for patients with advanced cancers. He is also currently a principal and co-investigator on a number of clinical trials that investigate novel therapeutic agents for ovarian, breast and lung cancers.

Dr Daniel Tan is a Senior Consultant Medical Oncologist at Division of Medical Oncology at National Cancer Centre Singapore, an Associate Professor at Duke-NUS Medical School, and a Senior Clinician-Scientist at Genome Institute of Singapore. Dr Tan has a specialist interest in thoracic, head and neck oncology and cancer drug development. Dr Tan’s work is focused on addressing the translational gap between basic science and clinical practice – particularly in improving our understanding of the determinants of response and resistance to targeted therapy and immunotherapy. In recognition of his research, he received the American Society of Clinical Oncology (ASCO) Merit Award twice, an ASCO Young Investigator Award and the SingHealth GCEO Outstanding Clinician-Researcher Award (2016). In 2019, he was awarded the Daniel C. Idhe Lectureship in Medical Oncology from the International Association for Study of Lung Cancer (IASLC) 2019 for his ‘extensive contributions in the lung cancer arena’. He was twice awarded the Clinician-Scientist Award from the National Medical Research Council of Singapore (NMRC). He has published more than 100 peer-reviewed articles, including top tier journals such as The New England Journal of Medicine, The Lancet, Nature, Nature Genetics, Nature Medicine and Journal of Clinical Oncology. Dr Tan received undergraduate training at St Bartholomew’s and Royal London Hospitals in the United Kingdom, obtained First Class honours for an Intercalated BSc in Tumor Biology from University College London (UCL), and undertook a postgraduate fellowship in drug development at the Royal Marsden Hospital. In 2017, he completed his PhD in Cancer Biology from Cancer Science Institute, National University of Singapore.

Enrico Ruffini is Full Professor of Thoracic Surgery at the University of Torino, Italy. He is the Chief of the Thoracic Surgery Unit in Torino, Italy since November 2018. He is the Director of the Thoracic Surgery Residency Program at the University of Torino, Italy. He is involved in the European Society of Thoracic Surgeons, formerly as Councillor (2012-2013) and officer in the role of Director of the ESTS annual meeting (2014-2017), and from 2019 to 2021 as ESTS president.  In the ESTS, he has also been the chair of the ESTS thymic working group until 2020. He served the ITMIG as secretary general for the years 2012-2014 and as member of several ITMIG committees. He has been a member of the Staging and Prognostic Factors Committee – Thymic domain (SPFC-TD) of the International Association for the Study of Lung Cancer (IASLC) for the years 2012-2016.  He is currently the Chair of the Staging and Prognostic Factors Committee – Thymic domain (SPFC-TD) of the International Association for the Study of Lung Cancer (IASLC) for the years 2017-2024. He is a reviewer for the following journals: European Journal of Cardio-thoracic Surgery, Journal of Thoracic Oncology, Lung Cancer, Journal of Thoracic Disease. He contributed to several textbooks on thoracic surgery and he is author or coauthor of 268 indexed journal articles, with an H-index of 51 (source: Scopus).

Fiona is a Radiation Oncologist at the Peter MacCallum Cancer Centre and Senior Research Fellow at the University of Melbourne. Fiona is a Director on the Board of the Trans-Tasman Radiation Oncology Group (TROG) and chairs the TROG Lung Subspecialty Working Party. Fiona is an active clinical trialist and leads a bench-to-bedside research programme that develops and clinically implements novel PET tracers to image the immune system as both biomarkers of response after systemic therapy and to guide the development of personalized, biologically driven approaches to radiotherapy treatment.

Gary Rodin is the Joint University of Toronto/University Health Network Harold and Shirley Lederman Chair in Psychosocial Oncology and Palliative Care and is Head of the Department of Supportive Care at the Princess Margaret Cancer Centre in Toronto. Dr. Rodin is the Director of the Global Institute of Psychosocial, Palliative and End-of-Life Care (GIPPEC) and a Professor of Psychiatry at the University of Toronto. He is a clinician-investigator who has published widely on the psychiatric and psychosocial aspects of cancer and other medical illnesses. Under his leadership, the Department of Supportive Care at the Princess Margaret has now achieved an international reputation for its academic and clinical excellence. Dr. Rodin has authored texts on Depression in the Medically Ill, and on the Psychiatric Aspects of Transplantation and is currently leading research on the psychological impact of advanced and terminal disease in affected patients and their families.

Dr. Heather Wakelee is a Professor of Medicine and Chief of the Division of Oncology at Stanford University, School of Medicine. She is the Deputy Director of the Stanford Cancer Institute, and Interim Medical Director of the Stanford Cancer Center. Dr. Wakelee serves as the President of the International Association for the Study of Lung Cancer (IASLC) and she is a Fellow of the American Society of Clinical Oncology (FASCO). She is a graduate of Princeton University and Johns Hopkins University School of Medicine and completed her post-graduate training at Stanford University. As an experience lung cancer investigator, Dr. Wakelee has authored or co-authored over 200 medical articles on lung cancer and thymic malignancies and is involved in dozens of clinical trials involving adjuvant therapy, immunotherapy, and anti-angiogenesis agents. Her research focuses on many specific lung cancer subtypes defined by specific mutations in EGFR, ALK, ROS1, RET, BRAF and others. Her translational efforts to date have involved collaborations with colleagues in medical oncology, thoracic radiation oncology, thoracic surgery, radiology, pulmonary medicine, and population sciences.

Professor of Surgery, Chief, Division of Thoracic Surgery, Keio University School of Medicine, Tokyo, Japan. Graduated from Keio University School of Medicine in 1983. Attending surgeon (Thoracic surgery, 1992-1998), Chief of Thoracic Surgery (1992-2014), and Deputy Director-Hospital (2012-2014) at the National Cancer Center Hospital, Tokyo. Professor of Surgery, Chief, Division of Thoracic Surgery, Keio University School of Medicine (2014-present). Doctor of Medical Science Degree from Keio University in 1997. IASLC activities include Chair of Staging and Prognostic Factors Committee (SPFC, 2016 – present), Executive Board Director (2012-2016), A Congress President for 18th World Conference on Lung Cancer. Vice President, Japan Lung Cancer Society.

Dr. Ignacio Ivan Wistuba, MD, is a professor of the Department of Translational Molecular Pathology with a Joint appointment in the Department of Thoracic/Head and Neck Medical Oncology, and co-director of the Khalifa Institute of Personalized Cancer Institute (IPCT) at the University of Texas (UT) MD Anderson Cancer Center (MDACC). He is also the director of the Thoracic Molecular Pathology Laboratory, director of the UT Lung SPORE Tissue Bank, director of the MDACC Institutional Tissue Bank, director of the ECOG-ACRIN (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network) Central Biorepository and Pathology Facility (EA CBPF), and pathologist for the SWOG Lung Cancer Committee. Dr. Wistuba is chair of the Pathology Committee of the International Association for the Study of Lung Cancer (IASLC). He is an associate editor of the Annals of Oncology and Cancer Prevention Research.

Professor Agarwal completed his post graduation at Tata Memorial Hospital, Mumbai, since then he joined his Alma mater as faculty in 1996 and became professor in 2006 and Head in November 2016. He has successfully mentored twenty six post graduates students, who are at prestigious positions in India and abroad. He has guided successfully several PhD students at Mumbai University and at HBNI (Deemed University). He is currently Member of Board of studies for HBNI and for several universities including National Board of Examination. He has been Post graduate examiner for various universities, National board of examination. Apart from being assessor for MCI and NABH, he has been on several committees for Government Of India, AIIMS, Government of Maharashtra and several departments as expert. He has special interests in head and neck cancer and lung cancers. He has been awarded several fellowships, AROI Fellowship, ECCO fellowship, Acta Oncologica IGRT fellow and is member of various scientific societies, author or co-author of more than 350 publications in national and international journals with more than 5500 citations in last five years. He is a regional editor of “Clinical Oncology’; official journal of Royal college of Radiologist. He has been reviewer and editorial board member several national and international cancer journals. He has been awarded honorary membership of ESTRO, a rare honour for radiation oncologist.

Jill Feldman is a lung cancer patient and advocate. When Jill was 13 years old, she lost her dad and two grandparents to lung cancer and then her mom and close aunt died of lung cancer when she was in her 20’s. She became a volunteer, an advocate and past president of LUNGevity Foundation before the unthinkable happened. In 2009, at 39 years old with four small children, Jill herself was diagnosed with EGFR positive lung cancer. Jill continues to be involved with LUNGevity. She is also Deputy Chair of IASLC’s patient advisory board and a member of The Chicago Institute of Translational Medicine’s patient advisory board. Jill is committed to understanding and promoting patient-centered research as a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, as a planning committee member on IASLC’s North America Conference on Lung cancer and as a member of the the ECOG-ACRIN Research Group’s patient advocate committee and thoracic committee. Jill has presented patient perspectives at conferences, including the World Conference on Lung Cancer hosted by IASLC and the virtual ASCO Education Program. She is a co-author of the ASTRO Guidelines for SBRT in early stage lung cancer that was published in an ASCO special article in the Journal of Clinical Oncology. 2017, Jill co-founded the EGFR Resisters, a grassroots, patient-driven community committed to accelerating research that will prolong and better the lives of people diagnosed with EGFRm lung cancer. Jill also continues to share her story in the media and at various events and participates in countless advocacy opportunities to shine a light on lung cancer and end the stigma associated with it.

Dr. Kelly, a renowned medical oncologist, is an active, long-standing member of the IASLC and a former member of the IASLC Board of Directors. She is recognized internationally for her expertise in lung cancer research and her career has been dedicated to providing enhanced cancer care through cutting-edge clinical trials. Dr. Kelly’s lung cancer research has involved all aspects of the disease from risk reduction and screening to treatment. She has been at the forefront of drug development to treat lung cancer throughout her career. Dr. Kelly most recently has served as Professor of Medicine and Associate Director for Clinical Research, University of California, Davis Comprehensive Cancer Center and held the Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research at UC Davis. She frequently lectures on lung cancer topics, nationally and internationally. Dr. Kelly has authored or co-authored more than 190 publications, including original papers, reviews, and book chapters.  She has served as the chair of the Lung Committee for SWOG, one of the nation’s leading cooperative cancer research organizations, since 2016.

Prof. Keith Kerr is Consultant Pathologist in the Department of Pathology, Aberdeen Royal Infirmary and an Honorary Professor at the University of Aberdeen, Aberdeen, UK. With specialism in thoracic pathology, Prof. Kerr has extensive expertise in NSCLC including: predictive and diagnostic biomarkers (particularly PD-L1 immunohistochemistry), mutations, molecular profiling, immunotherapy, and personalised medicine. Prof. Kerr has collaborated in the development of numerous guidelines for lung cancer diagnosis and management (such as RCPath, SIGN, NICE, BTS, and IASLC/CAP), including work as a lead author for the ESMO Consensus Guidelines on pathology and molecular biomarkers for NSCLC. Furthermore, Prof. Kerr enjoys extensive involvement with IASLC (currently Chair of the Pathology Committee, and Past Board member), is a BTS member of over 30 years; and serves as an Associate Editor for the Journal of Thoracic Oncology.

Mariam Jamal-Hanjani is a Thoracic Medical Oncologist and Group leader at the University College London Cancer Institute. Her early research in chromosomal instability and intratumour heterogeneity demonstrated the prognostic relevance of genomic instability in lung cancer. In 2012 she was awarded a Cancer Research UK Clinical Research Fellowship to complete her PhD studies with Prof. Charles Swanton in lung cancer evolution for which she was awarded the McElwain and the Sylvia Lawler Scientific Prizes. In 2016 she was awarded an NIHR Clinical Lectureship to continue her work in the field of cancer evolution and in 2021 she was awarded a Cancer Research UK Career Establishment Award to study the biological processes driving death in lung cancer. She is Principal Investigator of the TRACERx lung cancer evolution study, Chief Investigator of the PEACE research autopsy programme, and Chief Scientific Investigator of the first-in-human CHIRON study investigating the clinical activity of autologous clonal neoantigen T cells in patients with advanced non-small cell lung cancer. She is a co-investigator on two Cancer Grand Challenges focussed on the study of extrachromosomal DNA and cachexia, and her lab is focussed on studying tumour evolution and immune escape in the metastatic setting, and catabolic mediators of cancer cachexia.

Paul Van Schil was born on July 7, 1957 in Antwerp, Belgium. He graduated from medical school with great honour in 1982 at the Antwerp University in Belgium. After completing his training in general surgery, he became a fellow in the department of cardiothoracic surgery at the Antonius Hospital, Nieuwegein, the Netherlands. His doctoral thesis was entitled “Bronchial sleeve resection for lung cancer: long-term results” (University of Nijmegen, the Netherlands, 1992). In 1990 he became a staff member at the department of surgery of the Antwerp University Hospital. Currently, he is professor in thoracic and vascular surgery at the Faculty of Medicine, member of the Antwerp Surgical Training and Research Center (ASTARC) and consultant at the department of thoracic and vascular surgery of the Antwerp University Hospital. From October 2013 till October 2014 he was president of the European Association for Cardio-thoracic Surgery (EACTS).  In 2017 he became member of Board of Directors of the International Association for the Study of Lung Cancer (IASLC) and chair of the lung cancer domain of its Staging and Prognostic Factors Committee (SPFC). In September 2021 he became president-elect of IASLC. Currently, he is an associate editor of the European Respiratory Journal, Journal of Thoracic Oncology and Acta Chirurgica Belgica. His main interests are thoracic and vascular surgery with a special emphasis on lung cancer staging and therapy, lung metastases, thymoma and mesothelioma.

HRH Princess Dina Mired is a well-known passionate global advocate for Cancer Control and Non-Communicable Diseases and mother of a cancer survivor. HRH Princess Dina currently serves as the Honorary President of European Organization for Research and Treatment of Cancer (EORTC), Patron of International Society for Paediatric Oncology (SIOP), Member of WHO Expert Group for the Elimination of Cervical Cancer and Member the United Nations University (UNU) High level Advisory committee for Gender and Health Hub. Princess Dina is also the Special Envoy for Vital Strategies for NCD’s. Princess Dina served as President of the Union for International Cancer Control (UICC) from 2018-2020 was the first Arab and non-medical person to have been elected in such a prestigious global post.  Prior to that Princess HRH Princess Dina led the King Hussein Cancer Foundation (KHCF) as Director General from 2002 – till June 2016. Princess Dina transformed the non-profit into the most successful advocacy and fundraiser organization for cancer control efforts in Jordan and an internationally known brand and leader not only in Jordan but also in the global movement for people affected by cancer. On Sept 11th 2011 Princess Dina delivered, the keynote speech on behalf of all civil society on the opening of the United Nations General Assembly first ever High-Level Meeting on NCD’s. In September of 2018, Princess Dina was chosen again to speak at the third high level meeting on NCDs as “Eminent Champion of the fight against non-communicable diseases”.

Professor of National University of Singapore, Medicine. Senior Professor of National University of Singapore, Medicine. Senior Consultant, Division of Respiratory and Critical Care Medicine, National University Hospital, Director of Interventional Pulmonology. Interests include Lung Cancer, Interventional Pulmonology, Pleural Disease, COPD, Asthma, Respiratory Infections, Palliative Medicine

Born in Barcelona, Spain, and graduated from Barcelona University Medical School in 1980. He followed specialty training in thoracic surgery at the Jimenez Diaz Foundation, Madrid, Spain, and was board-certified in thoracic surgery in 1985. He received his PhD degree in 1986 from the Autonomous University of Madrid. He has been attending thoracic surgeon at Mutua Terrassa University Hospital, in Spain, since 1989, and clinical chief since 2017. He has authored over 160 articles in indexed journals. His major interests are lung cancer staging, surgical treatment of lung cancer, thoracic oncology in general, and Graham Greene.

Dr. Ross Soo is a senior consultant in the Department of Hematology-Oncology at the National University Cancer Institute Singapore, and an adjunct principal investigator at the Cancer Science Institute of Singapore, National University of Singapore. He received his medical degree from Monash University, underwent specialist training in Melbourne and Sydney, and subsequently became a fellow of the Royal Australasian College of Physicians and the Academy of Medicine, Singapore. He specialises in lung cancer and head and neck cancer and leads the lung tumour group at the National University Cancer Institute, Singapore. Dr. Soo’s professional affiliations include memberships of the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer, and the Singapore Society of Oncology. He sits on various committees including National Healthcare Group Domain-Specific Ethics Review Board, Ministry of Health Drug Advisory Committee (DAC), DAC-Oncology Drug Subcommittee, Medical Oncology Specialist Training Committee, Chapter of Medical Oncology Executive Committee, and the International Association for the Study of Lung Cancer Communications Committee.

Sanja Dacic is a Professor of Pathology, Vice Chair and Director of Anatomic Pathology at Yale School of Medicine.

Dr. Valerie W. Rusch is Attending Thoracic Surgeon, Vice Chair of Clinical Research, Department of Surgery and Member, Memorial Sloan-Kettering Cancer Center in New York, where she holds the Miner Family Chair in Intrathoracic Cancers. After residencies in general and cardiothoracic surgery at the University of Washington, she was a Faculty Associate at the MD Anderson Cancer Centre, then a faculty member at the University of Washington. She moved to MSKCC in 1989, where she served as Chief of Thoracic Surgery from 2000 to 2013. Dr. Rusch’s career has been devoted to thoracic surgical oncology, to clinical and translational research, and she has been PI for multiple NCI-sponsored Co-operative Group clinical trials. Dr. Rusch is a Past President of the American College of Surgeons, and has held leadership positions in ASCO, the Society for Thoracic Surgeons, the American Association for Thoracic Surgery, and the International Association for the Study of Lung Cancer. She has served as a Director and Chair of the American Board of Thoracic Surgery. Dr. Rusch is the recipient of multiple teaching awards, is author on more than 450 peer-reviewed publications, holds more than 50 visiting professorships and has delivered more than 400 invited lectures.